Treatment Action Group (TAG) welcomes the report published today by the World Health Organization TB Vaccine Accelerator Council on how to finance global, equitable access to new TB vaccines.
On Friday May 30, it was reported that National Institutes of Health (NIH) leadership has unilaterally terminated funding for HIV vaccine research consortia that were making significant progress toward solving the stern challenge of inducing protective broadly neutralizing antibodies against the virus.
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 3rd meeting of the WHO Director-General’s TB Vaccine Accelerator Council on May 20, 2025 in Geneva, Switzerland.
TAG is pleased to share the latest edition of our Tuberculosis Vaccines Pipeline Report, written by TB project co-director Mike Frick. The report provides the latest information on 17 vaccine candidates under clinical development and summarizes ongoing, planned, and recently completed clinical trials in two comprehensive tables.
TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 2nd meeting of the WHO Director-General’s TB Vaccine Accelerator Council in Geneva Switzerland.
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). The highlights presented here cover the results of several phase II TB prevention and treatment trials.
In October 2023, sixteen members of the global TB community developed a consensus statement on the inclusion of pregnant and breastfeeding women and persons in TB treatment and vaccines research.
This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium tuberculosis antigens and the IC31 adjuvant made by Valneva.
TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.